TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $26.39 million. The enterprise value is $25.64 million.
Important Dates
The next estimated earnings date is Thursday, March 26, 2026, after market close.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 1.31% in one year.
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +1.31% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 13.46% |
| Float | 9.56M |
Valuation Ratios
The trailing PE ratio is 87.00.
| PE Ratio | 87.00 |
| Forward PE | n/a |
| PS Ratio | 9.40 |
| Forward PS | n/a |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | 12.70 |
| P/OCF Ratio | 12.70 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 84.91 |
| EV / Sales | 9.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 12.40 |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.93 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.13 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 0.27% and return on invested capital (ROIC) is -3.12%.
| Return on Equity (ROE) | 0.27% |
| Return on Assets (ROA) | -2.73% |
| Return on Invested Capital (ROIC) | -3.12% |
| Return on Capital Employed (ROCE) | -5.07% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | $2.80M |
| Profits Per Employee | $302,000 |
| Employee Count | 1 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -63,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.15% in the last 52 weeks. The beta is 0.52, so TherapeuticsMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +76.15% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 51.09 |
| Average Volume (20 Days) | 67,892 |
Short Selling Information
The latest short interest is 47,648, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 47,648 |
| Short Previous Month | 87,461 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $2.80 million and earned $302,000 in profits. Earnings per share was $0.03.
| Revenue | 2.80M |
| Gross Profit | 2.80M |
| Operating Income | -1.71M |
| Pretax Income | 10,000 |
| Net Income | 302,000 |
| EBITDA | -1.32M |
| EBIT | -1.71M |
| Earnings Per Share (EPS) | $0.03 |
Full Income StatementBalance Sheet
The company has $7.12 million in cash and $6.48 million in debt, with a net cash position of $632,000 or $0.05 per share.
| Cash & Cash Equivalents | 7.12M |
| Total Debt | 6.48M |
| Net Cash | 632,000 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 27.44M |
| Book Value Per Share | 2.37 |
| Working Capital | 9.56M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.07M |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.07M |
| FCF Per Share | $0.18 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -61.16% and 10.80%.
| Gross Margin | 100.00% |
| Operating Margin | -61.16% |
| Pretax Margin | 0.36% |
| Profit Margin | 10.80% |
| EBITDA Margin | -47.32% |
| EBIT Margin | -61.16% |
| FCF Margin | 73.96% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.31% |
| Shareholder Yield | -1.31% |
| Earnings Yield | 1.15% |
| FCF Yield | 7.87% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
TherapeuticsMD has an Altman Z-Score of -33.5 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.5 |
| Piotroski F-Score | 5 |
